Literature DB >> 10433494

The effect of site-directed mutagenesis of two transmembrane serine residues on agonist-specific coupling of a cloned human alpha2A-adrenoceptor to adenylyl cyclase.

J E Rudling1, K Kennedy, P D Evans.   

Abstract

1. The effects of substitution of the Ser200 and Ser204 residues with alanine on the signalling properties of the cloned human alpha2A-adrenoceptor, stably expressed in Chinese hamster ovary (CHO) cell lines, have been investigated using noradrenaline and the structural isomers of octopamine. 2. The Ser-->Ala200 or the Ser-->Ala204 mutant forms of the alpha2A-adrenoceptor, when expressed in cells in the absence of pertussis toxin pretreatment, are two orders of magnitude more sensitive to inhibition of cyclic AMP production by (+/-)-para-octopamine and (+/-)-meta-octopamine, respectively, than cells expressing the wild-type receptor. Binding studies indicate that the effects are not due to an increased agonist affinity for the mutant receptors and that they are likely to be due to agonist-mediated conformational changes in receptor structure. 3. After incubation with pertussis toxin, (+/-)-meta-octopamine (100 microM and above) produced a stimulation of cyclic AMP levels in cells expressing the Ser-->Ala204 mutant form of the alpha2A-adrenoceptor but showed no stimulation in cells expressing the Ser-->Ala200 mutant receptor. Under these conditions (+/-)-para-octopamine did not produce any increases in cyclic AMP production in cells expressing either of the mutant receptor forms or the wild-type receptor. 4. The results emphasise the importance of the Ser200 and Ser204 residues of the alpha2A-adrenoceptor in exerting an inhibitory influence on the ability of (+/-)-para-octopamine and (+/-)-meta-octopamine respectively, to induce a receptor-agonist conformation capable of inhibiting forskolin-stimulation of cyclic AMP levels. 5. It is clear that Ser204 also prevents meta-octopamine from generating a receptor-agonist conformation that can increase cyclic AMP levels, emphasising the importance of this residue in the agonist-specific coupling of this receptor to different second messenger systems.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433494      PMCID: PMC1566090          DOI: 10.1038/sj.bjp.0702614

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  16 in total

1.  Simultaneous coupling of alpha 2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha 2C10, alpha 2C4, and alpha 2C2 adrenergic receptors to Gi and Gs.

Authors:  M G Eason; H Kurose; B D Holt; J R Raymond; S B Liggett
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

Review 2.  In vitro mutagenesis and the search for structure-function relationships among G protein-coupled receptors.

Authors:  T M Savarese; C M Fraser
Journal:  Biochem J       Date:  1992-04-01       Impact factor: 3.857

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Site-directed mutagenesis of alpha 2A-adrenergic receptors: identification of amino acids involved in ligand binding and receptor activation by agonists.

Authors:  C D Wang; M A Buck; C M Fraser
Journal:  Mol Pharmacol       Date:  1991-08       Impact factor: 4.436

Review 5.  Agonist-specific coupling of G-protein-coupled receptors to second-messenger systems.

Authors:  P D Evans; S Robb; T R Cheek; V Reale; F L Hannan; L S Swales; L M Hall; J M Midgley
Journal:  Prog Brain Res       Date:  1995       Impact factor: 2.453

Review 6.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

7.  Cloning, sequence analysis, and permanent expression of a human alpha 2-adrenergic receptor in Chinese hamster ovary cells. Evidence for independent pathways of receptor coupling to adenylate cyclase attenuation and activation.

Authors:  C M Fraser; S Arakawa; W R McCombie; J C Venter
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

8.  Pharmacological characterization of acetylcholine-stimulated [35S]-GTP gamma S binding mediated by human muscarinic m1-m4 receptors: antagonist studies.

Authors:  S Lazareno; N J Birdsall
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

9.  Coupling of expressed alpha 1B- and alpha 1D-adrenergic receptor to multiple signaling pathways is both G protein and cell type specific.

Authors:  D M Perez; M B DeYoung; R M Graham
Journal:  Mol Pharmacol       Date:  1993-10       Impact factor: 4.436

10.  Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems.

Authors:  S Robb; T R Cheek; F L Hannan; L M Hall; J M Midgley; P D Evans
Journal:  EMBO J       Date:  1994-03-15       Impact factor: 11.598

View more
  8 in total

1.  Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.

Authors:  P J Pauwels; F C Colpaert
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Conserved structural, pharmacological and functional properties among the three human and five zebrafish alpha 2-adrenoceptors.

Authors:  Jori O Ruuskanen; Jonne Laurila; Henri Xhaard; Ville-Veikko Rantanen; Karoliina Vuoriluoto; Siegfried Wurster; Anne Marjamäki; Minna Vainio; Mark S Johnson; Mika Scheinin
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

3.  A comparison of agonist-specific coupling of cloned human alpha(2)-adrenoceptor subtypes.

Authors:  J E Rudling; J Richardson; P D Evans
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

4.  Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.

Authors:  Juha M Peltonen; Tommi Nyrönen; Siegfried Wurster; Marjo Pihlavisto; Anna-Marja Hoffrén; Anne Marjamäki; Henri Xhaard; Liisa Kanerva; Juha-Matti Savola; Mark S Johnson; Mika Scheinin
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

5.  Agonist-specific coupling of a cloned human alpha1A-adrenoceptor to different second messenger pathways.

Authors:  Joanna Richardson; Heather Chatwin; Akira Hirasawa; Gozoh Tsujimoto; Peter D Evans
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-03-20       Impact factor: 3.000

6.  Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.

Authors:  Yolande Cordeaux; Adriaan P Ijzerman; Stephen J Hill
Journal:  Br J Pharmacol       Date:  2004-08-09       Impact factor: 8.739

7.  Modulation of Glucagon Receptor Pharmacology by Receptor Activity-modifying Protein-2 (RAMP2).

Authors:  Cathryn Weston; Jing Lu; Naichang Li; Kerry Barkan; Gareth O Richards; David J Roberts; Timothy M Skerry; David Poyner; Meenakshi Pardamwar; Christopher A Reynolds; Simon J Dowell; Gary B Willars; Graham Ladds
Journal:  J Biol Chem       Date:  2015-07-21       Impact factor: 5.157

8.  The signaling and selectivity of α-adrenoceptor agonists for the human α2A, α2B and α2C-adrenoceptors and comparison with human α1 and β-adrenoceptors.

Authors:  Richard G W Proudman; Juliana Akinaga; Jillian G Baker
Journal:  Pharmacol Res Perspect       Date:  2022-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.